Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

False Claims Act: US Justice Department Gives Pharma Early Christmas Present

Executive Summary

Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.

You may also be interested in...



Rx Drug Promotion: Potential Enforcement Worries

Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.

Will US Government Pursue Fewer False Claims Act Cases In 2019?

Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.

US False Claims Act Dismissal Motions Are Executive Branch Over-Reach, Whistleblowers Say

Justice Department lacks absolute right to dismiss meritorious qui tam complaints filed by affiliates of National Healthcare Analysis Group against numerous pharmaceutical companies, whistleblowers say, taking issue with government’s “personal attacks” on their business model and research practices.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel